摘要
目的评价及试析临床对糖尿病痛性周围神经病变患者应用α-硫辛酸+普瑞巴林联合治疗的临床现实意义。方法随机抽选于2016年10月—2018年10月期间该院收治的62例糖尿病痛性周围神经病变患者,按照门诊收治顺序分为两组。研究组(n=31)应用α-硫辛酸+普瑞巴林联合治疗,对照组(n=31)应用α-硫辛酸治疗。评价及对比两组的疗效、疼痛程度、神经传导速度(感觉神经、运动神经)、药物不良反应。结果研究组的疗效(87.10%)高于对照组(67.74%)(χ2=10.720 2,P=0.001 1);相比于对照组(2.05±0.46)分,研究组的疼痛程度(3.47±0.71)分明显下降(χ2=9.3455,P=0.000 1 <0.05);两组的神经传导速度比较差异无统计学意义(P>0.05),但研究组的神经传导速度略高。用药后,研究组出现1例嗜睡、1例头晕,7 d后自愈,对照组未出现明显不良反应。结论临床对糖尿病痛性周围神经病变患者应用α-硫辛酸+普瑞巴林联合治疗,可扩大治疗优势,有效减轻患者疼痛,同时还可修复神经,且未出现严重药物不良反应,安全性较高,是一种理想的治疗方案。
Objective To evaluate and analyze the clinical significance of clinical application of α-lipoic acid + pregabalin in patients with diabetic painful peripheral neuropathy. Methods A total of 62 patients with diabetic peripheral neuropathy admitted to our hospital from October 2016 to October 2018 were randomly selected and divided into two groups according to the order of outpatient treatment. The study group (n=31) was treated with α-lipoic acid + pregabalin, and the control group (n=31) was treated with α-lipoic acid. The efficacy, pain level, nerve conduction velocity (sensory nerve, motor nerve), and drug side effects of the two groups were evaluated and compared. Results The efficacy of the study group (87.10%) was higher than that of the control group (67.74%)(χ^2=10.720 2, P=0.001 1 <0.05);the degree of pain in the study group compared with the control group (2.05±0.46)points and (3.47±0.71)points was significantly decreased (χ^2=9.3455, P=0.000 1,P<0.05). The difference of nerve conduction velocity between the two groups was not significant (P>0.05), but the nerve conduction velocity of the study group was slightly higher. After treatment, the study group showed 1 case of lethargy, 1 case of dizziness, and self-healing after 7 days. No obvious adverse reactions occurred in the control group. Conclusion The combination of α-lipoic acid and pregabalin in patients with diabetic painful peripheral neuropathy can expand the therapeutic advantage, effectively alleviate the pain of patients, and also repair nerves without serious side effects and safety. It is an ideal treatment plan.
作者
李宜臻
LI Yi-zhen(Department of Endocrinology, Wenjiang District People's Hospital, Chengdu, Sichuan Province, 611130 China)
出处
《中外医疗》
2019年第10期127-129,共3页
China & Foreign Medical Treatment